Use of desmopressin to prevent bleeding in surgery

European Journal of Surgery

Volumn 164, Issue 1, 1998, Pages 5-11

  Flordal, Per Anders ^a  

^a DANDERYD HOSPITAL   (Sweden)

Author keywords

Aspirin; Blood loss; Blood transfusion; Coagulation; Desmospressin; Platelet function; Surgery

Indexed keywords

ACETYLSALICYLIC ACID; APROTININ; DESMOPRESSIN; NONSTEROID ANTIINFLAMMATORY AGENT;

BLEEDING; BLEEDING TENDENCY; BLOOD TRANSFUSION; BREAST RECONSTRUCTION; CHOLECYSTECTOMY; CLINICAL TRIAL; CORONARY ARTERY BYPASS GRAFT; DRUG HYPERSENSITIVITY; DRUG MECHANISM; HEART SURGERY; HEMOPHILIA A; HIP ARTHROPLASTY; HUMAN; PRIORITY JOURNAL; REVIEW; SPINE FUSION; SURGICAL PATIENT; THROMBOCYTE DYSFUNCTION; THROMBOCYTE FUNCTION; THROMBOSIS; VON WILLEBRAND DISEASE;

EID: 0031937551     PISSN: 11024151     EISSN: None     Source Type: Journal    
DOI: 10.1080/110241598750004887     Document Type: Review

References (98)

1. Åberg M, Hedner U, Bergentz S-E. Effect of dextran on factor VIII (antihemophilic factor) and platelet function. Ann Surg 1978; 189: 243-247.
2. Allen FB, Gerson JI, Davey FR. Platelet inhibition by nitroprusside and nitroglycerin. Anesthesiology 1979; 51 (suppl 75): S75.
3. Andersson TLG, Solem JO, Tengborn L, Vineg E. Effects of desmopressin acetate on platelet aggregation, von Willebrand factor, and blood loss after cardiac surgery with extracorporeal circulation. Circulation 1990; 81: 872-878.
4. Ansell J, Klassen V, Lew R et al. Does desmopressin acetate prophylaxis reduce blood loss after valvular heart operations? J Thorac Cardiovasc Surg 1992; 104: 117-123.
5. Blombäck M, Bredbacka S, Bremme K et al. Koagulationsnytt 1997. Stockholm: Scandinavian University Press, 1996.
6. Borg T, Modig J. Potential anti-thrombotic effects of local anaesthetics due to their inhibition of platelet aggregation. Acta Anaesthesiol Scand 1985; 29: 739-742.
7. Brown MR, Swygert TH, Whitten CW, Hebeler R. Desmopressin acetate following cardiopulmonary bypass: evaluation of coagulation parameters. J Cardiothorac Anesth 1989; 3: 726-729.
8. Buchanan MR, Blister SJ. Individual variation in the effects of ASA on platelet function: implications for the use of ASA clinically. Can J Cardiol 1995; 11: 221-227.
9. Campbell FW, Addonizio Jr VP. Platelet function alterations during cardiac surgery. In: Ellison N, Jobes DR, eds. Effective hemostasis in cardiac surgery: a Society of Cardiovascular Anesthesiologists Monograph. Philadelphia: WB Saunders, 1988.
10. Casas J, Zuazu-Jausoro I, Mateo J et al. Aprotinin versus desmopressin for patients undergoing operations with cardiopulmonary bypass. A double-blind placebo-controlled study. J Thorac Cardiovasc Surg 1995; 110: 1107-1117.
11. Cattaneo M, Harris A, Strömberg U, Mannucci P. The effect of desmopressin on reducing blood loss in cardiac surgery - a meta-analysis of double-blind, placebo-controlled trials. Thromb Haemost 1995; 74: 1064-1070.
12. Cattaneo M, Tenconi PM, Alberca I, Garcia VV, Mannucci PM. Subcutaneous desmopressin (DDAVP) shortens the prolonged bleeding time in patients with liver cirrhosis. Thromb Haemost 1990; 64: 358-360.
13. Chard RB, Kam CA, Nunn GR, Johnson DC, Meldrum-Hanna W. Use of desmopressin in the management of aspirin-related and intractable haemorrhage after cardiopulmonary bypass. Aust NZ J Surg 1990; 60: 125-128.
14. Chuang H, Horng Y, Li Y et al. [Clinical assessment of desmopressin to reduce blood loss in patients after cardiopulmonary bypass]. Ma Tsui Hsueh Tsa Chi 1993; 31: 35-42.
15. Clagett G, Valentine R, Myers S, Chervu A, Heller J. Does desmopressin improve hemostasis and reduce blood loss from aortic surgery? A randomized, doubleblind study. J Vasc Surg 1995; 22: 223-230.
16. Cohen J. Weighted kappa: nominal scale agreement with provision for scaled disagreement or partial credit. Psychological Bulletin 1968; 70: 213-220.
17. Cosgrove III DM, Heric B, Lytle BW et al. Aprotinin therapy for reoperative myocardial revascularization: a placebo-controlled study. Ann Thorac Surg 1992; 54: 1031-1038.
18. Cronberg S, Robertson B, Nilsson IM, Niléhn JE. Suppressive effect of dextran on platelet adhesiveness. Thromb Diath Haemorrh 1966; 16: 384-394.
19. Czer LSC, Bateman TM, Gray RJ et al. Treatment of severe platelet dysfunction and hemorrhage after cardiopulmonary bypass: reduction in blood product usage with desmopressin. J Am Coll Cardiol 1987; 9: 1139-1147.
20. Despotis GJ, Levine VL, Filos KS et al. Evaluation of a new point-of-care test that measures PAF-mediated acceleration of coagulation in cardiac surgical patients. Anesthesiology 1996; 85: 1311-1323.
21. Dilthey G, Dietrich W, Spannagl M, Richter JA. Influence of desmopressin acetate (DDAVP) on homologous blood requirement in cardiac surgical patients pretreated with platelet-inhibiting drugs. J Cardiothorac Vasc Anesth 1990; 6 (suppl 3): 32.
22. Dilthey G, Dietrich W, Spannagl M, Richter JA. Influence of desmopressin acetate on homologous blood requirements in cardiac surgical patients pretreated with aspirin. J Cardiothorac Vasc Anesth 1993; 7: 425-430.
23. Drouet L, Scrobohaci ML, Boudaoud S, Vilain G. Desmopressin (dDAVP): a powerful general hemostation agent? Nouv Rev Fr Hematol 1989; 31: 163-165.
24. Fiore LD, Brophy MT, Lopez A, Janson P, Deykon D. The bleeding time response to aspirin. Identifying the hyperresponder. Am J Clin Pathol 1990; 94: 292-296.
25. Flordal PA. Haemostatic mechanisms and blood loss in total hip replacement, with special reference to the effects of desmopressin. Thesis. Danderyd: Karolinska Institutet, 1992.
26. Flordal PA. Measurement of blood loss in clinical studies. Eur J Anaesthesiol 1997; 14 (suppl 14): 35-37.
27. Flordal PA, Ljungström K-G. Renal effects of high dose desmopressin and dextran. A study in normal subjects and in patients undergoing total hip replacement. Acta Anaesthesiol Scand 1993; 37: 1-6.
28. Flordal PA, Ljungström K-G, Ekman B, Neander G. Effects of desmopressin on blood loss in hip arthroplasty. Controlled study in 50 patients. Acta Orthop Scand 1992; 63: 381-385.
29. Flordal PA, Ljungström K-G, Fehrm A. Desmopressin and postoperative thromboembolism. Thromb Res 1992; 68: 429-433.
30. Flordal PA, Sahlin S. Use of desmopressin to prevent bleeding complications in patients treated with aspirin. Br J Surg 1993; 80: 723-724.
31. Flordal PA, Svensson J. Hemostatic effects of ephedrine. Thromb Res 1992; 68: 295-302.
32. Frankville DD, Harper GB, Lake CL, Johns RA. Hemodynamic consequences of desmopressin administration after cardiopulmonary bypass. Anesthesiology 1991; 74: 988-996.
33. Gratz I, Koehler J, Olsen D et al. The effect of desmopressin acetate on postoperative hemorrhage in patients receiving aspirin therapy before coronary artery bypass operations. J Thorac Cardiovasc Surg 1992; 104: 1417-1422.
34. Guay J, Reinberg C, Poitras B et al. A trial of desmopressin to reduce blood loss in patients undergoing spinal fusion for idiopathic scoliosis. Anesth Analg 1992; 75: 405-410.
35. Guyuron B, Vaughan C, Schlecter B. The role of DDAVP (desmopressin) in orthognathic surgery. Ann Plast Surg 1996; 37: 516-519.
36. Hackmann T, Gascoyne RD, Naiman SC et al. A trial of desmopressin (1-desamino-8-D-vasopressin) to reduce blood loss in uncomplicated cardiac surgery. N Engl J Med 1989; 321: 1437-1443.
37. Haith LR, Patton ML. Goldman WT, McCutchan KM. Diminishing blood loss during operation for burns. Surg Gynecol Obstet 1993; 176: 119-123.
38. Hedderich GS, Petsikas DJ, Cooper BA et al. Desmopressin acetate in uncomplicated coronary artery bypass surgery: a prospective randomized clinical trial. Can J Surg 1990; 33: 33-36.
39. 14C]5-hydroxytryptamine release. Br J Haematol 1977; 36: 427-436.
40. Henny CP, Odoom JA, ten Cate H et al. Effects of extradural bupivacaine on the haemostatic system. Br J Anaesth 1986; 58: 301-305.
41. Hirsh J, Levine MN. Low molecular weight heparin. Blood 1992; 79: 1-17.
42. Horrow JC, van Riper DF, Strong MD, Brodsky I, Parmet JL. Hemostatic effects of tranexamic acid and desmopressin during cardiac surgery. Circulation 1991; 84: 2063-2070.
43. Hunt BJ, Yacoub M. Aprotinin and cardiac surgery. BMJ 1991; 303: 660-661.
44. John L, Rees G, Kovacs I. Inhibition of platelet function by heparin: an aetologic factor in postbypass hemorrhage. J Thorac Cardiovasc Surg 1993; 105: 816-822.
45. Johnson RG, Murphy JM. The role of desmopressin in reducing blood loss during lumbar fusions. Surg Gynecol Obstet 1990; 171: 223-226.
46. Kapsch D, Silver D. Heparin-induced thombocytopenia with thrombosis and haemorrhage. Arch Surg 1981; 116: 1423-1427.
47. Karnezis TA, Stulberg SD, Wixson RL, Reilly P. The hemostatic effects of desmopressin on patients who had total joint arthroplasy. J Bone Joint Surg 1994: 76A: 1545-1550.
48. Kladetzky R-G, Popov-Cenic S, Müller N, Hack G, Lang U. The effect of dextran 70 on the intra- and postoperative behaviour of haemostasis. Bibl Anat 1977; 16: 463-465.
49. Kobrinsky NL, Israels ED, Gerrard JM et al. Shortening of bleeding time by 1-deamino-8-D-arginine vasopressin in various bleeding disorders. Lancet 1984; i:: 1145-1148.
50. Kobrinsky NL, Letts RM, Patel LR et al. 1-desamino-8-D-arginine vasopressin (desmopressin) decreases operative blood loss in patients having Harrington rod spinal fusion surgery. A randomized, double-blinded, controlled trial. Ann Intern Med 1987; 107: 446-450.
51. Koscielny J, Radtke H, Ziemer S et al. Normalisierung der Thrombozytenfunktion durch Desmopressin [Normalisation of platelet function by means of DDAVP]. Anästh Intensivmed 1995; 36: 205-210.
52. Kuitunen AH. Haemostatic responses to desmopressin acetate after primary coronary artery bypass surgery. Ann Chir Gynaecol 1992; 81: 11-18.
53. Langman MJS. Epidemiologic evidence on the association between peptic ulceration and antiinflammatory drug use. Gastroenterology 1989; 96: 640-646.
54. Lazenby WD, Russo I, Zadeh BJ et al. Treatment with desmopressin acetate in routine coronary artery bypass surgery to improve postoperative hemostasis. Circulation 1990; 82:IV (suppl 5): 413-419.
55. Lecompte T, Luo SK, Stieltjes N, Lecrubier C, Samama MM. Thrombocytopenia associated with low-molecular-weight heparin. Lancet 1991; 338: 1217.
56. Lethagen S, Nilsson IM. DDAVP-induced enhancement of platelet retention: its dependence on platelet-von Willebrand factor and the platelet receptor GP IIb/IIIa. Eur J Haematol 1992; 49: 7-13.
57. Lethagen S, Rugarn P, Bergqvist D. Blood loss and safety with desmopressin or placebo during aorto-iliac graft surgery. Eur J Vasc Surg 1991; 5: 173-178.
58. Lethagen S, Rugarn P, Åberg M, Nilsson IM. Effects of desmopressin acetate (DDAVP) and dextran on hemostatic and thromboprophylactic mechanisms. Acta Chir Scand 1990; 156: 597-602.
59. Lisander B, Jacobsson S-A, Ivarsson I, Vegfors M, Engdahl O. Giving both enoxaparin and dextran increases the need for transfusion in revision hip arthroplasty. Eur J Surg 1996; 162: 861-866.
60. LoCicero III J, Massad M, Matano J. Effect of desmopressin acetate on hemorrhage without identifiable cause in cardiopulmonary bypass patients. Am Surg 1991; 57: 165-168.
61. Mannucci PM, Canciani MT, Rota L, Donovan BS. Response of factor VIII/von Willebrand factor to DDAVP in healthy subjects and patients with haemophilia A and von Willebrand's disease. Br J Haematol 1981; 47: 283-293.
62. Mannucci PM, Carlsson S, Harris AS. Desmopressin, surgery and thrombosis. Thromb Haemost 1994; 71: 154-155.
63. Mannucci PM, Lusher JM. Desmopressin and thrombosis. Lancet 1989; ii: 675-676.
64. Mannucci PM, Remuzzi G, Pusineri F et al. Deamino-8-D-arginine vasopressin shortens the bleeding time in uremia. N Engl J Med 1983; 308: 8-12.
65. Mannucci PM, Ruggeri ZM, Pareti FI, Capitano A. 1-deamino-8-D-arginine vasopressin: a new pharmacological approach to the management of haemophilia and von Willebrand's disease. Lancet 1977; i: 869-872.
66. Mannucci PM, Vicente V, Vianello L et al. Controlled trial of desmopressin in liver cirrhosis and other conditions associated with a prolonged bleeding time. Blood 1986; 67: 1148-1153.
67. Mannucci PM, Aberg M, Nilsson IM, Robertson B. Mechanism of plasminogen activator and factor VIII increase after vasoactive drugs. Br J Haematol 1975; 30: 81-93.
68. Marquez J, Koehler S, Strelec SR et al. Repeated dose administration of desmopressin acetate in uncomplicated cardiac surgery: a prospective, blinded, randomized study. J Cardiothorac Vasc Anesth 1992; 6: 674-676.
69. van der Meer J, Hillege HL, Terres W, Ascoop CA, Dunselman PH. Aprotinin in coronary bypass surgery reduces blood loss but is associated with an increased risk of vein graft occlusion and clinical thrombotic events. Br J Haematol 1994; 87 (suppl 1): 189.
70. Mongan PD, Hosking MP. The role of desmopressin acetate in patients undergoing coronary artery bypass surgery. A controlled clinical trial with thromboelastographic risk stratification. Anesthesiology 1992; 77: 38-46.
71. Nazzal M, Owunwanne A, Christenson JT. Direct platelet effect of low molecular weight dextran in small calibre PTFE grafts. Eur J Vasc Surg 1991; 5: 169-172.
72. Nilsen DWT, Haerem J, Westheim A, Skjennald A, Grendahl H, Godal HC. Venous thrombosis following diagnostic transvenous catheterization by percutaneous catheter insertion: an evaluation of desmopressin as a thromboprophylactic agent. Thromb Haemost 1984; 52: 121-123.
73. Odoom JA, Dokter PWC, Sturk A, ten Cate JW, Sih IL, Bovill JG. The influence of epidural analgesia on platelet function and correlation with plasma bupivacaine concentrations. Eur J Anaesthesiol 1988; 5: 305-312.
74. de Prost D, Barbier-Boehm G, Hazebroucq J et al. Desmopressin has no beneficial effect on excessive postoperative bleeding or blood product requirements associated with cardiopulmonary bypass. Thromb Haemost 1992; 68: 106-110.
75. Reich DL, Hammerschlag BC, Rand JH et al. Desmopressin acetate is a mild vasodilatator that does not reduce blood loss in uncomplicated cardiac surgical procedures. J Cardiothorac Vasc Anesth 1991; 2: 142-145.
76. Reynolds L, Nicolson S, Jobes D et al. Desmopressin does not decrease bleeding after cardiac operation in young children. J Thorac Cardiovasc Surg 1993; 106: 954-958.
77. Richardson DW, Robinson AG. Desmopressin. Ann Intern Med 1985; 103: 228-239.
78. Rocha E, Hidalgo F, Llorens R, Melero J, Arroyo J, Paramo J. Randomized study of aprotinin and DDAVP to reduce postoperative bleeding after cardiopulmonary bypass surgery. Circulation 1994; 90: 921-927.
79. Rocha E, Llorens R, Páramo JA, Arcas R, Cuesta B, Martin Trenor A. Does desmopressin acetate reduce blood loss after surgery in patients on cardiopulmonary bypass? Circulation 1988; 77: 1319-1323.
80. Rodeghiero F, Castaman G, Dini E. Epidemiolological investigation of the prevalence of von Willebrand's disease. Blood 1987; 69: 454-459.
81. Royston D. High-dose aprotinin therapy: a review of the first five years' experience. J Cardiothorac Anesth 1992; 6: 76-100.
82. Salmenperä M, Kuitunen A, Hynynen M, Heinonen J, Hemodynamic responses to desmopressin acetate after CABG: a double-blind trial. J Cardiothorac Vasc Anesth 1991; 2: 146-149.
83. Salmenperä M, Kuitunen A, Hynynen M, Heinonen J, Fyhrquist F. Does the anesthetic technique affect hemostasis after cardiac surgery? Anesthesiology 1991; 75 (3A): A74.
84. Salzman EW, Weinstein MJ, Weintraub RM et al. Treatment with desmopressin acetate to reduce blood loss after cardiac surgery. A double-blind randomized trial. N Engl J Med 1986; 314: 1402-1406.
85. Schmied H, Kurz A, Sessler DI, Kozek S, Reiter A. Mild hypothermia increases blood loss and transfusion requirements during total hip arthroplasty. Lancet 1996; 347: 289-292.
86. Schott U, Sollén C, Axelsson K, Rugarn P, Allvin A. Desmopressin acetate does not reduce blood loss during total hip replacement in patients receiving dextran. Acta Anaesthesiol Scand 1995; 39: 592-598.
87. Schulman S. DDAVP - the multipotent drug in patients with coagulopathies. Transfusion Medicine Reviews 1991; V: 132-144.
88. Schulman S, Johnsson H. Heparin, DDAVP and the bleeding time. Thromb Haemost 1991; 65: 242-244.
89. Schulman S, Johnsson H, Lindstedt M. Desmopressin as a haemostatic agent in patients with disorders of primary haemostasis. Eur J Surg 1991; 157: 647-652.
90. Seear MD, Wadsworth LD, Rogers PC, Sheps S, Ashmore PG. The effect of desmopressin acetate (DDAVP) on postoperative blood loss after cardiac operations in children. J Thorac Cardiovasc Surg 1989; 98: 217-219.
91. Sheridan DP, Card RT, Pinilla JC et al. Use of desmopressin acetate to reduce blood transfusion requirements during cardiac surgery in patients with acetylsalicylic-acid-induced platelet dysfunction. Can J Surg 1994; 37: 33-36.
92. Solem JO, Kure HH, Lührs C, Johnsson P, Steen S, Tengborn L. The effect of desmopressin (DDAVP) on blood loss and hemostasis in uncomplicated coronary artery bypass surgery. Manuscript 1988.
93. Temeck B, Bachenheimer L, Katz N, Coughlin S, Wallace R. Desmopressin acetate in cardiac surgery: a double-blind, randomized study. South Med J 1994; 87: 611-615.
94. Törnebohm E, Bratt G, Granqvist S, Lockner D, Egberg N. A pilot study: desmopressin (DDAVP) in the treatment of deep venous thrombosis. Thromb Res 1987; 45: 635-643.
95. Verstraete M, Kienast J. Pharmacology of the interaction between platelets and vessel wall. In: Chesterman CN, ed. Thrombosis and the vessel wall. (Hoffbrand AV, Lasch HG, Nathan DG, Luzzatto L, Waller HD, Weatherall DJ, eds. Clinics in haematology; vol 15). London: Saunders, 1986: 493-508.
96. Weksler B, Gillick M, Pink J. Effect of propranolol on platelet function. Blood 1977; 49: 185-196.
97. Werner EJ, Broxson EH, Tucker EL, Giroux DS, Shults J, Abshire TC. Prevalence of von Willebrand disease in children: a multiethnic study. J Pediatr 1993; 123: 893-898.
98. Wingate GF, Lewis VL, Green D, Wiedrich TA. Koenig WJ. Desmopressin decreases operative blood loss in spinal cord injury patients having flap reconstruction of pelvic pressure sores. Plastic Reconstr Surg 1992; 89: 279-282.